Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review
eJHaem · 2026-10 · 7 (5)
DOI: 10.1002/jha2.70385 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift eJHaem, online erschienen am 19.09.2026. Verfasst von Mahmood Aldapt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology Mayo Clinic Jacksonville Florida USA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pennsylvania State University.
Abstract (Originalsprache)
Background
TP53 mutations ( TP53 m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Methods
A PRISMA‐guided systematic review of EMBASE and PubMed identified cohort studies of adult Ph–negative MPN with molecularly confirmed TP53 m. Pooled proportions with 95% CI were generated using random‐effects models; survival outcomes were summarized descriptively.
Results
Eleven retrospective cohort studies ( N = 603) met inclusion criteria. TP53 m were uncommon overall (3%, 95% CI: 1–13; I 2 = 97%) but substantially enriched in MF or AP/BP‐MPN cohorts (10%, 95% CI: 4–24; I 2 = 89%). Among TP53 m patients, disease distribution included AP/BP‐MPN (33%, 95% CI: 26–41), MF (31%, 95% CI: 15–54), ET (16%, 95% CI: 5–41), and PV (11%, 95% CI: 4–27). Single‐ and multi‐hit TP53 were present in comparable proportions (52% vs. 48%), with a pooled mean VAF of 37.48% (95% CI: 30.73–44.24; I 2 = 97%). Unfavorable karyotype was identified in 42%. Median OS was: 37.4–72 months in PV, 44.4–54.6 months in ET, 11.6–24.7 months in MF, and 4.5–6 months in AP/BP‐MPN. In CP‐MPN, multi‐hit TP53 conferred worse OS (9.5–18.5 months) versus single‐hit disease (38 months to not reached); this distinction was absent in AP/BP‐MPN. Leukemic transformation occurred in 35% (95% CI: 16–60; I 2 = 93%) across two reporting cohorts, and allo‐HCT was utilized in only 16% (95% CI: 13–19; I 2 = 12%).
Conclusions
TP53 m Ph–negative MPN are enriched in advanced‐phase disease, carry comparable proportions of single‐hit and multi‐hit allelic configurations with high clonal burden, and demonstrate a clinically important survival gradient. Allelic status is a key prognostic determinant in CP‐MPN but loses significance in AP/BP‐MPN where outcomes are uniformly dismal. Standardized molecular reporting and prospective clinical trials are needed. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology Mayo Clinic Jacksonville Florida USA.
- Department of Pharmacy Heart Hospital Hamad Medical Corporation Doha Qatar.
- Department of Internal Medicine Unity Hospital/Rochester Regional Health Rochester New York USA.
- Department of Internal Medicine Penn State - M.S. Hershey Medical Center Hershey Pennsylvania USA.
- Division of Hospital Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA.
- Department of Hematology National Center for Cancer Care and Research Hamad Medical Corporation Doha Qatar.
Förderung
- Pennsylvania State University
Zitieren
APA
Aldapt, M., Kaddoura, R., Saleh, A. O., Najim, M., Salem, A., Al-Mashdali, A. F., Muthanna, B., Aweer, R. A., Rabadi, M., & Mohamed, S. F. (2026). Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review. eJHaem, 7(5). https://doi.org/10.1002/jha2.70385
Vancouver
Aldapt M, Kaddoura R, Saleh AO, Najim M, Salem A, Al-Mashdali AF, et al. Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review. eJHaem. 2026;7(5). doi:10.1002/jha2.70385
BibTeX
@article{Aldapt2026,
author = {Aldapt, Mahmood and Kaddoura, Rasha and Saleh, Ahmed O and Najim, Mostafa and Salem, Ahmad and Al-Mashdali, Abdulrahman F and Muthanna, Bassam and Aweer, Ruba Adel and Rabadi, Marrita and Mohamed, Shehab F},
title = {Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/jha2.70385}
}
EUVIMED